# VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

> **NCT00903773** · PHASE1 · COMPLETED · sponsor: **Tibotec BVBA** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C
- Kidney Diseases

## Interventions

- **DRUG:** telaprevir

## Key facts

- **NCT ID:** NCT00903773
- **Lead sponsor:** Tibotec BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2010-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903773, "VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00903773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*